Bone Marrow Suppression; Teratogen
Bone Marrow Suppression: severe
Carcinogen in humans
Mutagen, Teratogen: Probable in humans
Infertility associated with this drug
Monitoring data
Perform weekly hematological testing to determine hemoglobin, total & differential leukocyte counts, & quantitative platelet counts. Perform WBC during the first 3 to 6 weeks of therapy, at 3 or 4 days after each weekly complete blood cell counts.
Patient counseling
Package inserts
Additional information
Updated: January 2018
This information provides a SUMMARY of Black Box data from product labeling and does not address all warnings, precautions, or important safety data found in the product insert. It is NOT intended for use in medical decision-making. Patients and healthcare professionals should always consult the most recent product information insert available from the manufacturer, and contact a physician or care provider with any questions. This table may not be complete and may not include all boxed warnings. It is periodically updated with supplemental information from FDA safety alerts, labeling announcements, and new drug approvals.
Formweb is a product of Rpharmy, LLC.
Visit our website at rpharmy.com for more information on online formularies featuring Black Box Warnings.